Morgan Stanley and Atlanta Capital Management Company, LLC filed Amendment No. 6 to Schedule 13G with the SEC on November 13, 2026, disclosing their combined beneficial ownership of Class A Common Stock in Dolby Laboratories, Inc. as of September 30, 2026.
Zhen Li filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of approximately 9.7% of the common stock of ADARx Pharmaceuticals, Inc., as of September 30, 2026.
Dayah Energy Partners, L.P., Dayah Energy GP, LLC, Dayah Capital LLC, and Jonathan Siscovick filed Amendment No. 2 to Schedule 13G with the SEC on November 13, 2026, disclosing a combined beneficial ownership position in Ramaco Resources, Inc. Class A Common Stock as of …
AWM Investment Company, Inc. filed Amendment No. 2 to a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 17,490,062 shares of Kopin Corp common stock as of September 30, 2026.
GreenLight Ventures, LLC filed Amendment No. 1 to its Schedule 13D with the SEC on November 13, 2026, disclosing updated beneficial ownership of common stock in Nexalin Technology, Inc. following the issuance of a third tranche of shares on November 10, 2026.
ARCH Venture Management, LLC and affiliated entities filed Amendment No. 3 to Schedule 13D with the SEC on November 13, 2026, reporting beneficial ownership of common stock in Prime Medicine, Inc. as of the triggering event date of November 12, 2026.
Autolus Therapeutics plc filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 13, 2026, to register an additional 10,653,613 ordinary shares represented by American Depositary Shares under its 2018 Equity Incentive Plan.
Rail Vision Ltd. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 13, 2026, to register an additional 300,000 ordinary shares issuable under its Amended Share Option Plan.
Lyell Immunopharma, Inc. filed a Form S-3 registration statement with the SEC on November 13, 2026, covering the resale of up to 7,428,040 shares of common stock by selling stockholders who received those shares in a private placement that closed on November 4, 2026.
SHF Holdings, Inc. filed a current report on Form 8-K on November 13, 2026, disclosing a Nasdaq delisting determination, a waiver extending its registration statement filing deadline, and the issuance of more than 63 million shares of common stock through Series B Preferred Stock …